Sanofi-Aventis U.S. LLC plans to ask a federal judge Friday to delay the first bellwether trial over breast cancer drug Taxotere, citing a U.S. Supreme Court decision that requires a “completely different approach” to federal preemption and already prompted postponement of a separate trial over nausea drug Zofran.

In an Aug. 9 motion, Sanofi attorney Douglas Moore, of New Orleans-based Irwin Fritchie Urquhart & Moore, sought a “brief continuance” of a Sept. 16 trial, the first of among 12,000 lawsuits coordinated in New Orleans federal court alleging Taxotere caused permanent hair loss, or alopecia areata.